Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

Metadata

Authors/Creators:	Schöffski, P Wozniak, A Stacchiotti, S Rutkowski, P Blay, J-Y Lindner, LH Strauss, SJ Anthoney, A Duffaud, F Richter, S Grünwald, V Leahy, MG Reichardt, P Sufliarsky, J van der Graaf, WT Sciot, R Debiec-Rychter, M van Cann, T Marréaud, S Lia, M Raveloarivahy, T Collette, L Bauer, S
Commentary on:	Schöffski, P, Wozniak, A, Stacchiotti, S et al. (20 more authors) (2017) Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Annals of Oncology, 28 (12). pp. 3000-3008. ISSN 0923-7534
Dates:	Accepted: 18 September 2017 Published (online): 5 May 2018 Published: 1 February 2019
Institution:	The University of Leeds
Depositing User:	Symplectic Publications
Date Deposited:	31 Oct 2019 09:39
Last Modified:	31 Oct 2019 09:39
Status:	Published
Publisher:	Oxford University Press
Identification Number:	https://doi.org/10.1093/annonc/mdx823
Related URLs:	Author

Schöffski, P, Wozniak, A, Stacchiotti, S, Rutkowski, P, Blay, J-Y, Lindner, LH, Strauss, SJ, Anthoney, A, Duffaud, F, Richter, S, Grünwald, V, Leahy, MG, Reichardt, P, Sufliarsky, J, van der Graaf, WT, Sciot, R, Debiec-Rychter, M, van Cann, T, Marréaud, S, Lia, M, Raveloarivahy, T, Collette, L and Bauer, S Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. (deposited 30 Oct 2019 16:49)
- Schöffski, P, Wozniak, A, Stacchiotti, S, Rutkowski, P, Blay, J-Y, Lindner, LH, Strauss, SJ, Anthoney, A, Duffaud, F, Richter, S, Grünwald, V, Leahy, MG, Reichardt, P, Sufliarsky, J, van der Graaf, WT, Sciot, R, Debiec-Rychter, M, van Cann, T, Marréaud, S, Lia, M, Raveloarivahy, T, Collette, L and Bauer, S Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. (deposited 31 Oct 2019 09:39) [Currently Displayed]

CORE (COnnecting REpositories)